Our Partnering Strategy
At Elpiscience, we aim to forge long-term, mutually beneficial strategic relationships with leading biopharmaceutical companies and academic institutions to accelerate the development of potentially transformative immunotherapies. Our entrepreneurial culture and unique operational advantages enable nimble decision-making and highly collaborative partnerships to efficiently drive global immunotherapy innovation.
Our Partners
Astellas
On December 28 2023, Elpiscience Biopharma, Ltd. and Astellas Pharma Inc. (TSE: 4503) announced a research collaboration and license agreement for novel bi-specific macrophage engagers (BiME®;), ES019 and another program. The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up to two additional programs to be included in the collaboration. If Astellas exercises its option, Elpiscience will grant Astellas the exclusive right to further research, develop, manufacture and commercialize the products for each program.
Compass
In January 2021, we entered into a license agreement with TRIGR (now Compass), under which we were granted an exclusive license to further develop, manufacture and commercialize the VEGF/DLL4 bispecific antibody ES104 (CTX-009/tovecimig) in Greater China.
Inhibrx
In April 2018, we entered into a license agreement with Inhibrx, Inc., under which we were granted an exclusive license to further develop, manufacture and commercialize an OX40 agonist antibody ES102(INBRX-106) in Greater China.
Junshi
In May 2020 we entered a clinical collaboration with Junshi Biosicences to evaluate the safety, tolerability and potential early efficacy signal of ES102, a next generation OX40 agonistic antibody, in combination with toripalimab (TUOYI®), an anti-PD-1 mAb and immune checkpoint inhibitor for the treatment of patients with advanced solid tumors and hematological tumors.